• Recruiting

NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002

Updated: Sep 30

CELMoD

MM-002

CC-92480-MM-002 (NCT03989414)

NCT03989414: A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)


Phase 1/2 study evaluating CC-92480 in combination with standard treatments in pts with RRMM.

CC-92480

NDMM : Newly diagnosed Multiple Myeloma

RRMM : Relapsed & Refractory Multiple Myeloma

NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma


A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)


This is an open-label, multicenter, Phase 1/2 study to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.


Sponsor

Celgene


Multiple locations

International Study

 

ClinicalTrials.gov Identifier: NCT03989414

Official Title: A Phase 1/2 Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

First Posted : June 18, 2019


Click here for details on ClinicalTrials.gov

 

cereblon E3 ubiquitin ligase modulating agent CC-92480

CC-92480


Mezigdomide (Code C146660)

CC 92480

CC-92480

CELMoD CC-92480

Cereblon E3 Ligase Modulation Drug CC-92480

Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480

Cereblon Modulator CC-92480

Mezigdomide

MEZIGDOMIDE

 

Drug: CC-92480

Drug: Bortezomib

Drug: Dexamethasone

Drug: Daratumumab

Drug: Carfilzomib

Drug: Elotuzumab

Drug: Isatuximab

 

2731 CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

Program: Oral and Poster Abstracts

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II

Hematology Disease Topics & Pathways:

Biological, Clinical Trials, Plasma Cell Disorders, Clinical Research, Diseases, Therapies, Immunotherapy, Lymphoid Malignancies

Sunday, December 12, 2021, 6:00 PM-8:00 PM

Learn more

 

11/04/2021: PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across a wide range of hematologic diseases at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in Atlanta, Georgia, and virtually, from December 11 to 14, 2021. Data from more than 80 company-sponsored studies will be featured, including 23 oral presentations, highlighting key research and development programs in lymphomas, leukemias, multiple myeloma and myeloid diseases, and showcasing our commitment to delivering transformative medicines across major hematologic diseases.

First disclosure of preliminary results from the Phase 1/2 MM-002 study of CELMoD® CC-92480 in combination with dexamethasone and bortezomib in patients with R/R multiple myeloma

Click here for details.

 

OAB-053 - Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)


#IMS2022 - 19th International Myeloma Society Annual Meeting; August 25-27, 2022 - LA, California

IMS 2022 Abstract EBook

https://www.myelomasociety.org/


#IMS2022 - 19th International Myeloma Society Annual Meeting; Aug 25-27, LA California (themyelomaclinicaltrials.com)

 

- Multiple locations

- International Study


- Texas: The University of Texas MD Anderson Cancer Center Houston

- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver

- Florida: Moffitt Cancer Center Tampa

- Georgia: Emory University Atlanta

- Illinois: University of Chicago

- Massachusetts: Massachusetts General Hospital Boston

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Michigan: Barbara Ann Karmanos Cancer Institute Detroit

- Minnesota: Mayo Clinic Rochester Minnesota

- New Jersey: Hackensack University Medical Center

- North Carolina: Wake Forest Baptist Health Winston-Salem

- Tennessee: Sarah Cannon Research Institute Nashville

- Washington: Swedish Cancer Inst Seattle

 

Locations

United States, Colorado

United States, Florida

United States, Georgia

United States, Illinois

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, New Jersey

United States, North Carolina

United States, Ohio

United States, Tennessee

United States, Texas

United States, Washington

Canada, Alberta

Canada, Nova Scotia

Canada, Ontario

Canada, Quebec

Europe

France

Germany

Italy

Spain

Czechia

Denmark

Greece

 

RELATED POSTS

NCT05552976: Phase 3: (SUCCESSOR-2) CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM

Click here for details


NCT05519085: Phase 3: (SUCCESSOR-1) CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM

Click here for details


NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma

Click here for details


NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma

Click here for details


MEZIGDOMIDE

Posts Archive